Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153100 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
A Phase 1 study of Diabetes, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01153100: Completed Phase 1 study of Diabetes, sponsored by University of Colorado, Denver.
NCT01153100 is a Phase 1 study of Diabetes that has completed, run by University of Colorado, Denver. The registered enrollment target is 60 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01153100, a Phase 1 study of Diabetes, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators anticipate that the use of Glargine will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued.
Conditions Studied
Interventions
- DRUG Glargine
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT01153100 record still lists
NCT01153100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Glargine is the first listed.
NCT01153100 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01153100 about?
NCT01153100 is a clinical study titled "Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy". The investigators anticipate that the use of Glargine will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued...
What is the current status of trial NCT01153100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-04. Estimated completion is 2012-02.
What conditions does trial NCT01153100 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT01153100?
The interventions under investigation include: Glargine (DRUG).
Who is sponsoring clinical trial NCT01153100?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01153100 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01153100's enrollment target sits among peer trials
60 235th of 338 higher than 96 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia